Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart plus TPF induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (Phase 2)
ChiCTR2600119884Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Objective Response Rate and 3-year Failure-Free Survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600119884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119884.